Literature DB >> 1757078

Immunolocalization of tumour necrosis factor alpha in lung tissue from patients dying with adult respiratory distress syndrome.

J R Nash1, P J McLaughlin, C Hoyle, D Roberts.   

Abstract

Using a mouse monoclonal antibody raised against recombinant human tumour necrosis factor alpha (TNF alpha), we have studied immunostained paraffin-embedded autopsy lung tissues from 13 patients dying with adult respiratory distress syndrome and 10 control patients dying of unrelated conditions. Material from 12 of the 13 cases showed positive staining, strong in six, less strong in the remaining six. TNF alpha was located principally within epithelial cells resembling type II pneumocytes in both early and late stages of adult respiratory distress syndrome. In the early stages the TNF alpha positive cells were scattered and appeared disorganized, but in later cases they formed an epithelium. The cells were confirmed as epithelial by their staining pattern with monoclonal antibodies reactive with epithelial, cytokeratin and macrophage antigens, and by double staining for epithelial membrane antigen and TNF alpha. In the control group, staining for TNF alpha was confined to very occasional plump type II pneumocytes, and a weak reaction in bronchial lining cells. Macrophages were only weakly stained in either group. It is suggested that TNF alpha is synthesized (or possibly absorbed) by type II pneumocytes and may be involved in the production of, or recovery from, adult respiratory distress syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1757078     DOI: 10.1111/j.1365-2559.1991.tb00228.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  An immunohistochemical method for the detection of tumour necrosis factor alpha in cytospins of human bronchoalveolar lavage cells.

Authors:  S Hamilton; M Healy; P Corris; R Scott
Journal:  Histochem J       Date:  1995-06

2.  Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury.

Authors:  R H Bardales; S S Xie; R F Schaefer; S M Hsu
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

3.  Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model.

Authors:  L Tremblay; F Valenza; S P Ribeiro; J Li; A S Slutsky
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

Review 4.  Acute respiratory distress syndrome in the septic surgical patient.

Authors:  Jose L Balibrea; Javier Arias-Díaz
Journal:  World J Surg       Date:  2003-10-28       Impact factor: 3.352

5.  The inflammatory cytokines tumor necrosis factor alpha and interleukin-1beta stimulate phosphatidylcholine secretion in primary cultures of rat type II pneumocytes.

Authors:  E Benito; M A Bosch
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396

6.  Tumor necrosis factor-alpha-induced inhibition of phosphatidylcholine synthesis by human type II pneumocytes is partially mediated by prostaglandins.

Authors:  J Arias-Díaz; E Vara; C García; J L Balibrea
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

7.  Differential induction of human monocyte transforming growth factor beta 1 production and its regulation by interleukin 4.

Authors:  C L Miller-Graziano; D Zhu; K Kodys
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

8.  Cellular localization of tumor necrosis factor (TNF)-alpha transcripts in normal bowel and in necrotizing enterocolitis. TNF gene expression by Paneth cells, intestinal eosinophils, and macrophages.

Authors:  X Tan; W Hsueh; F Gonzalez-Crussi
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

9.  Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS.

Authors:  John M Nicholls; Jagdish Butany; Leo L M Poon; Kwok H Chan; Swan Lip Beh; Susan Poutanen; J S Malik Peiris; Maria Wong
Journal:  PLoS Med       Date:  2006-01-03       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.